Is your immunotherapy working?
Finding hope with Signatera™
When Steven was diagnosed with metastatic melanoma, he started to lose hope. After his oncologist ordered circulating tumor DNA (ctDNA) testing with Signatera, Steven found the peace of mind he needed to rediscover his purpose and joy. His tumor tissue was sequenced for its unique genomic variants, and now his oncologist uses serial blood draws to confirm that Steven remains cancer-free during immunotherapy. Watch Steven’s story now to learn more.
Learn how Signatera works
Understand your Signatera test results
Discover our BESPOKE study of Signatera-guided immuno-oncology (IO) therapy
Be a part of something truly groundbreaking. Join Natera’s BESPOKE IO study to make a difference for people who, like you, are managing cancer with immunotherapy or immuno-oncology (IO) treatment. The study will examine the use of Signatera and the impact it has on treatment decisions for clinical outcomes in cancer patients being treated through immunotherapy. The study will enroll more than 1,500 patients. Natera and its collaborators will collect data on clinical decisions, benefits, and outcomes from enrolled participants for up to two years.
Visit our Signatera BESPOKE IO page to learn more about joining the study.